Previous 10 | Next 10 |
DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020 PR Newswire CUERTINO, Calif., Oct. 5, 2020 CUERTINO, Calif., Oct. 5, 2020 /PRNewswir...
DURECT Corporation to Participate in Fireside Chat at H.C. Wainwright 4th Annual NASH Investor Conference PR Newswire CUPERTINO, Calif., Sept. 30, 2020 CUPERTINO, Calif. , Sept. 30, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today th...
Durect ([[DRRX]] -3.1%) has dosed the first patient in its Phase 2 study, evaluating DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury.The 80-subject trial is designed to evaluate safety and efficacy of DUR-928, with primary efficacy endpoint of composite of sur...
DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury PR Newswire CUPERTINO, Calif., Sept. 23, 2020 CUPERTINO, Calif. , Sept. 23, 2020 /PRNewswire/ -- DURECT C...
DURECT Corporation Announces Design of Phase 2b AH Study (AHFIRM) Phase 2b study in subjects with Alcoholic Hepatitis to evaluate safety and efFIcacy of DUR-928 treatMent (AHFIRM) PR Newswire CUPERTINO, Calif., Sept. 22, 2020 CUPERTINO, Calif. , Sept. 22, 2...
CUPERTINO, Calif. , Sept. 10, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will participate in the HC Wainwright 22nd Annual Global Investment Conference, Cantor Fitzgerald Virtual Global Healthcare Conference and Oppenheimer Fall Healthcare L...
CUPERTINO, Calif. , Aug. 27, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the presentation of pharmacokinetic (PK) data from a Phase 2a study of DUR-928 in alcoholic hepatitis (AH) at the Digital International Liver Congress™ 2020 (EASL) , taking...
CUPERTINO, Calif. , Aug. 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President, CEO, Michael H. Arenberg , Chief Financial Officer and Dr. WeiQi Lin , Executive Vice President of R&D will be participating in a fireside chat hoste...
Quick Take PainReform ( PRFX ) intends to raise $23 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a reformulated pain relief medication for post-operative pain reduction. PRFX management has performed well...
CUPERTINO, Calif. , Aug. 5, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, Michael H. Arenberg , Chief Financial Officer and Dr. WeiQi Lin , Executive Vice President of R&D will be participating in a fireside cha...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...